Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human Kininogen-1/KNG1-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Immunoreactivity: |
Measured by its ability to inhibit papain cleavage of a fluorogenic peptide substrate Z-FR-AMC. The IC50 value approximately is 1 nM. |
Gene Symbol: |
KNG1 |
Gene ID: |
3827 |
Uniprot ID: |
KNG1_HUMAN |
Immunogen Region: |
Gln 19-Ser 427 |
Immunogen: |
Recombinant Human Kininogen-1/KNG1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gln 19-Ser 427) of human Kininogen-1 (Accession #NP_000884) fused with a 6×His tag at the C-terminus. |
Post Translational Modifications | Bradykinin: Bradykinin is inactivated by ACE, which removes the dipeptide Arg-Phe from its C-terminus. Bradykinin is released from kininogen by plasma kallikrein. Hydroxylation of Pro-383 occurs prior to the release of bradykinin. Phosphorylated by FAM20C in the extracellular medium. N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans. (Microbial infection) Bradykinin is generated upon proteolytic cleavage by S.pyogenes SpeB to produce hypotension during septic shock. |
Function | Kininogens are inhibitors of thiol proteases. HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII.HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. LMW-kininogen inhibits the aggregation of thrombocytes. LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. Bradykinin: The active peptide bradykinin is a potent vasodilatator that is released from HMW-kininogen shows a variety of physiological effects: (A) influence in smooth muscle contraction, (B) induction of hypotension, (C) natriuresis and diuresis, (D) decrease in blood glucose level, (E) it is a mediator of inflammation and causes (E1) increase in vascular permeability, (E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action). |
Protein Name | Kininogen-1Alpha-2-Thiol Proteinase InhibitorFitzgerald FactorHigh Molecular Weight KininogenHmwkWilliams-Fitzgerald-Flaujeac Factor Cleaved Into - Kininogen-1 Heavy Chain - T-KininIle-Ser-Bradykinin - BradykininKallidin I - Lysyl-BradykininKallidin Ii - Kininogen-1 Light Chain - Low Molecular Weight Growth-Promoting Factor |
Database Links | Reactome: R-HSA-114608Reactome: R-HSA-140837Reactome: R-HSA-375276Reactome: R-HSA-381426Reactome: R-HSA-416476Reactome: R-HSA-418594Reactome: R-HSA-8957275 |
Cellular Localisation | SecretedExtracellular Space |
Alternative Protein Names | Kininogen-1 proteinAlpha-2-Thiol Proteinase Inhibitor proteinFitzgerald Factor proteinHigh Molecular Weight Kininogen proteinHmwk proteinWilliams-Fitzgerald-Flaujeac Factor Cleaved Into - Kininogen-1 Heavy Chain - T-Kinin proteinIle-Ser-Bradykinin - Bradykinin proteinKallidin I - Lysyl-Bradykinin proteinKallidin Ii - Kininogen-1 Light Chain - Low Molecular Weight Growth-Promoting Factor proteinKNG1 proteinBDK proteinKNG protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance